In clinical practice, the assessment of disease activity in SLE is performed by means of disease activity scores Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) or additional testing for the complement components 3 and 4 (C3, C4) and anti-dsDNA titers [4]. This evidence concerns the gene C3 and systemic lupus erythematosus.